|P. Therasse, MD, PhD, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium, offers sound suggestions for improving clinical studies on new cancer therapies. The presenter covered Phase I-III protocol designs and identified avoidable pitfalls. This report includes useful information for clinical investigators and practitioners alike.|
|Phase I aims, pitfalls, and remedies||
Estimation of the maximum tolerated dose (MTD) and dose
limiting serious toxicity (DLT) is the major aim of Phase I
studies. A pool of adult patients with advanced disease allows
giving stepped doses of the test agent to 3 or 4 pts/group.
The results help select the MTD and DLT for use in later studies.
Therasse identifies several pitfalls in Phase I studies which make the results difficult to apply:
Phase I studies might be improved by (1) better preclinical models for selecting the starting dose, (2) new methods to expose fewer patients to the experimental drug, and (3) random assignment of patients in the dose titration.
|Phase II aims, pitfalls, and remedies||
In this phase, the investigator seeks to detect antitumor
activity, further identify drug toxicity and attempts to
quantify safety and efficacy. The selected adults have
advanced disease with no available established chemotherapy.
Under very special conditions, children and elderly patients
may be included.
Currently, there are at least 10 experimental designs available for conducting Phase II studies. Each design has a specific endpoint and should be utilized under specific conditions. Two designs are used regularly: the Gehan method for early Phase II (J Chron Dis 1961;13:346-353) and that of Simon (Controlled Clinical Trials 1989;10:1-10) and Fleming (Biometrics 1982;38: 143-151) for late Phase II.
In Therasse's opinion, common pitfalls in Phase II include the use of:
Future studies could avoid investigator bias by randomly assigning patients to test or control treatment.
|Phase III aims, pitfalls, and remedies||
In most anticancer trials, the therapeutic effect is small and
requires special attention for controlling systematic (bias) and
random errors. A Phase III clinical trial is started to compare
the efficacy of a new treatment with standard care. Comparison
with the natural history of the disease is needed when nothing
else is available. The trial also determines whether the
experimental agent produces less toxicity compared with the
reference drug or improves the quality of life when efficacy
may be equivalent.
The study protocol requires patient randomization to assigned treatment(s) and balanced groups in multicenter evaluations. Special attention to uncontrolled variables, such as time, is necessary to assure the validity of the observed therapeutic effect. There are basically three protocol designs for Phase III studies: (1) parallel group (A vs B), (2) crossover (A followed by B and B by A), and (3) factorial using two or more treatments given alone or combined.
Endpoints in a Phase III trial often include:
Therasse recommends measuring the time of an event from the date of randomization to treatment.
Common pitfalls in Phase III trials merit consideration:
Phase III intergroup trials have special requirements. These include (1) setting a common study objective, (2) agreeing on a common methodology, and (3) having an independent group in charge of quality control and data management.
Therasse envisions future Phase III protocols incorporating interim analyses and early stopping rules. An independent data monitoring committee is needed for trials of more than 500 patients and recruitment periods over 4 years in duration.
For professional correspondence, please contact Dr. Therasse by E-mail at: email@example.com
Presented at The European Cancer Conference (ECCO 9), September
Copyright © 1997 Conrad Group, Inc. All Rights Reserved
Eugene A. Conrad, PhD, MPH / ISSN 1078-2230 / November 1997
Send comments to: ConradNote@aol.com